2879-14-3

Basic information

• Product Name: 8-Phenyl-1H-purine-2,6(3H,7H)-dione
• Synonyms: 8-Phenyl-1H-purine-2,6(3H,7H)-dione
• CAS NO: 2879-14-3
• Molecular Formula: C₁₁H₈N₄O₂
• Molecular Weight: 228.21
• Mol File: 2879-14-3.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 8-Phenyl-1H-purine-2,6(3H,7H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Phenyl-1H-purine-2,6(3H,7H)-dione(2879-14-3)
• EPA Substance Registry System: 8-Phenyl-1H-purine-2,6(3H,7H)-dione(2879-14-3)

Safety Data

• Hazardous Substances Data: 2879-14-3(Hazardous Substances Data)

Usage

Uses

8-Phenylxanthine is used as a reactant in the preparation of xanthine derivatives as adenosine A1 receptor antagonists.

Upstream product

• 98-88-4 benzoyl chloride 
• 3240-72-0 5,6-diaminouracil 
• 3240-72-0 5,6-diaminouracil 
• 5350-41-4 trimethylbenzylammonium bromide 
• 56-37-1 N-benzyl-N,N,N-triethylammonium chloride 
• 100-52-7 benzaldehyde 
• 543-80-6 barium(II) acetate 
• 98-95-3 nitrobenzene 
• 42965-55-9 5,6-diaminouracil sulfate 
• 82160-94-9 8-Phenyl-7-hydroxyxanthine 
• 32704-59-9 ethyl 5-amino-2-phenylimidazole-4-carboxylate 
• 57-13-6 urea 

Downstream Products

• 412918-55-9 2,6-dichloro-8-phenyl-9H-purine 

Relevant articles and documents

Synthesis and biological properties of C-2, C-8, N-9 substituted 6-(3-chloroanilino)-purine derivatives as cyclin-dependent kinase inhibitors. Part II

In this study, C-2, C-8, N-9 substituted 6-(3-chloroanilino)purine derivatives were synthesized and their inhibitory effects on cyclin-dependent kinases (CDK2, 4) as well as their cytotoxicities were evaluated. The effects of substituents at the C-2, C-8, and N-9 positions of the substituted purine were investigated. Among the compounds tested, [6-(3-chloroanilino)-2-(2-hydroxymethyl-4-hydroxypyrrolidyl)- 9-isopropylpurine] (4h) was the most active inhibitor of CDK2 with IC50 of 0.3μM i.e. a two-fold increased inhibitory activity as compared to roscovitine. Results from structure-activity relationship studies should allow the design of more potent and selective CDK2 inhibitors, which may provide an effective therapy for cancer or other CDK-dependent diseases.

OXIDATIVE CYCLOCONDENSATION OF TRIALKYLAMMONIUM SALTS WITH DIAMINES

-